Are serotonin-norepinephrine reuptake inhibitors (SNRIs) effective for treating abnormal sexual behaviors such as hypersexuality?

SNRIs Are NOT Effective for Treating Abnormal Sexual Behaviors

SNRIs (serotonin-norepinephrine reuptake inhibitors) are not recommended for treating hypersexuality or compulsive sexual behaviors—in fact, they commonly CAUSE sexual dysfunction as an adverse effect rather than treating it. The evidence shows that SSRIs (selective serotonin reuptake inhibitors), not SNRIs specifically, have documented efficacy for reducing hypersexual behaviors, while SNRIs share similar sexual side effect profiles without specific evidence for treating these conditions 1, 2, 3.

Key Evidence and Reasoning

SNRIs Cause Sexual Dysfunction, Not Treat It

The available guidelines consistently document that SNRIs cause sexual adverse events at rates comparable to SSRIs 4. Recent pharmacovigilance data confirms that SNRIs exhibit significant signals for sexual dysfunction, with these effects being underreported in clinical practice 5. This makes them inappropriate for treating conditions characterized by excessive sexual behavior.

SSRIs (Not SNRIs) Have Evidence for Hypersexuality Treatment

The World Federation of Societies of Biological Psychiatry guidelines specifically recommend selective serotonin reuptake inhibitors (SSRIs) as the most relevant pharmacological treatment for compulsive sexual behavior disorder (CSBD), not SNRIs 3. The mechanism appears related to serotonergic modulation reducing sexual desire and arousal 1, 2.

The treatment algorithm for hypersexuality/CSBD is:

• First-line: Psychoeducation and psychotherapy (always required)
• Pharmacological options when needed: SSRIs or naltrexone
• For comorbid paraphilias: Consider hormonal agents (antiandrogens, LHRH agonists)
• SNRIs are not mentioned as treatment options 3

Critical Clinical Pitfalls

Confusing Sexual Dysfunction Treatment vs. Hypersexuality Treatment

The evidence provided addresses two opposite problems:

• Sexual dysfunction (hypoactive desire): SNRIs and SSRIs CAUSE this problem 4, 5, 6
• Hypersexuality (hyperactive desire): SSRIs may TREAT this problem 1, 2, 3

SNRIs have no documented role in treating abnormal sexual behaviors. They share the sexual side effect burden of SSRIs without specific evidence for therapeutic benefit in hypersexuality.

Receptor Mechanisms Matter

The therapeutic effect in hypersexuality appears mediated primarily through serotonin transporter blockade and effects on 5-HT1B and 5-HT2A receptors 5. While SNRIs affect serotonin, the addition of norepinephrine reuptake inhibition does not appear to provide additional benefit for sexual behavior disorders and may complicate the side effect profile with cardiovascular risks 4.

Practical Recommendations

If treating compulsive sexual behavior disorder:

• Start with SSRIs (fluoxetine, sertraline, or paroxetine have the most data) 1, 2, 3
• Avoid SNRIs—they lack specific evidence and carry similar sexual side effects plus additional cardiovascular concerns 4
• Consider naltrexone as an alternative first-line pharmacological option 3
• Reserve hormonal treatments for cases with comorbid paraphilias 1, 2, 3

If a patient on SNRIs develops sexual dysfunction:

• This is an expected adverse effect occurring in a significant proportion of patients 4, 5
• Consider switching to bupropion, which has lower rates of sexual adverse events 4
• Sexual dysfunction may persist even after SSRI/SNRI discontinuation in some cases 7